Literature DB >> 23323544

Assessing the accuracy and reproducibility of computer-assisted analysis of (123) I-FP-CIT SPECT using BasGan (V2).

A Skanjeti1, T Angusti, M Iudicello, F Dazzara, G M Delgado Yabar, E Trevisiol, V Podio.   

Abstract

BACKGROUND AND
PURPOSE: Over the last two decades (123) I-FP-CIT-SPECT, has been used to discriminate neurodegenerative Parkinsonian syndrome from other diseases. BasGan is a freely available software that assists (123) I-FP-CIT-SPECT evaluation by estimating semiquantitative values for each basal nucleus and compares the results to a database of healthy subjects. The aims of this study were: (1) to assess the accuracy of qualitative analysis and of semiquantitative, BasGan-assisted evaluations of (123) I-FP-CIT-SPECT; (2) to compare the accuracy of both methods when applied to "doubtful" cases; (3) to appreciate the reproducibility of the BasGan-assisted evaluations.
MATERIALS AND METHODS: Seventy-eight patients were included in this 4-year follow-up study. The diagnostic cut-off for semiquantitative uptake values of each basal nucleus was determined based on ROC curves analysis. Accuracy scores were calculated for the entire population and for "doubtful" cases. Intra- and interoperator reproducibility was assessed.
RESULTS: Accuracy of the software-assisted analyses was high for data from each nucleus. In "doubtful" exams accuracy was higher when using BasGan as opposed to relying solely on visual assessment. Intra- and interoperator reproducibility of the BasGan-assisted evaluations was good to excellent.
CONCLUSION: BasGan-assisted evaluations of (123) I-FP-CIT-SPECT were very useful, particularly in "doubtful" cases. Multicenter studies are mandatory before routine use of BasGan.
Copyright © 2013 by the American Society of Neuroimaging.

Entities:  

Keywords:  123I-FP-CIT-SPECT; BasGan (V2); Movement disorder; Parkinson disease; doubtful exams

Mesh:

Substances:

Year:  2013        PMID: 23323544     DOI: 10.1111/jon.12008

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  6 in total

1.  Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease.

Authors:  Sule Tinaz; Christopher Chow; Phillip H Kuo; Elizabeth A Krupinski; Hal Blumenfeld; Elan D Louis; George Zubal
Journal:  Clin Nucl Med       Date:  2018-01       Impact factor: 7.794

2.  Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.

Authors:  Helen Schmitz-Steinkrüger; Catharina Lange; Ivayla Apostolova; Franziska L Mathies; Lars Frings; Susanne Klutmann; Sabine Hellwig; Philipp T Meyer; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-31       Impact factor: 9.236

3.  Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.

Authors:  G Martino; M Capasso; M Nasuti; L Bonanni; M Onofrj; A Thomas
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

4.  Comparison of machine learning and semi-quantification algorithms for (I123)FP-CIT classification: the beginning of the end for semi-quantification?

Authors:  Jonathan Christopher Taylor; John Wesley Fenner
Journal:  EJNMMI Phys       Date:  2017-11-29

5.  Striatal dopamine transporter imaging in Parkinson's disease drug-naïve patients: focus on sexual dysfunction.

Authors:  Elena Contaldi; Luca Magistrelli; Silvia Gallo; Cristoforo Comi
Journal:  Neurol Sci       Date:  2022-04-06       Impact factor: 3.830

6.  Computer-aided diagnosis for (123I)FP-CIT imaging: impact on clinical reporting.

Authors:  Jonathan Christopher Taylor; Charles Romanowski; Eleanor Lorenz; Christine Lo; Oliver Bandmann; John Fenner
Journal:  EJNMMI Res       Date:  2018-05-08       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.